Peptides for mood and depression — the research landscape beyond conventional antidepressants

The monoamine hypothesis of depression — the idea that depression is caused by insufficient serotonin, norepinephrine, or dopamine — has been the organizing framework for antidepressant pharmacology since the 1950s. It is also incomplete, possibly in fundamental ways. The clinical observation that most SSRIs increase synaptic serotonin within hours but produce antidepressant effects, when they occur at all, over weeks, has always been difficult to reconcile with a simple deficiency model. More recent research has implicated neuroinflammation, with elevated inflammatory cytokines detectable in a significant subset of depressed patients and with inflammatory challenges in healthy volunteers reliably producing depressive symptoms. The neurotrophin hypothesis focuses on brain-derived neurotrophic factor: BDNF is reduced in depression, appears to recover with effective treatment, and its role in hippocampal neurogenesis — the growth of new neurons in a region critical to mood, memory, and HPA axis regulation — has become a central thread in understanding how antidepressants actually work. The kynurenine pathway diversion describes what happens when inflammatory cytokines cause tryptophan to be metabolized toward neurotoxic quinolinic acid rather than toward serotonin — a mechanism that directly links inflammation and mood chemistry. The microbiome enters the picture through gut-brain axis communication that includes immune signaling, vagal nerve transmission, and microbial production of neuroactive compounds. The HPA axis — dysregulated in many people with depression, producing either elevated or dysregulated cortisol rhythms — ties stress biology directly to depressive neurobiology.

This multiplicity of mechanisms is not an argument against treatment. It is context for why treatment is complex, why a single-mechanism intervention doesn't work for everyone, and why research has explored other threads.

Semax has probably the most developed research profile among peptides studied for mood and depression, at least within the Russian clinical tradition. A synthetic ACTH-derived peptide, Semax has been studied for its capacity to upregulate BDNF — one of the primary proposed mechanisms of antidepressant action — and for its effects on dopamine and serotonin systems in the prefrontal cortex. Russian clinical studies have examined Semax in depressive disorders, anxiety-depression overlap states, and cognitive sequelae of chronic stress. The mechanistic alignment is genuine: if BDNF deficiency is part of depressive neuropathology, and if Semax reliably increases BDNF, the hypothesis generates testable predictions. The evidence base is limited by Western standards — primarily Russian-language, smaller sample sizes, methodological differences from what the FDA requires for drug approval — but it is a real research tradition rather than folklore. Semax is not FDA-approved for any psychiatric indication.

Selank, discussed for its anxiolytic properties in stress contexts, enters the depression discussion through its relevance to anxiety-depression overlap, which is among the most common clinical presentations. Many people diagnosed with depression carry significant anxiety, and the anxiolysis that Selank may help support without sedation is relevant to both components of the picture. Its GABAergic and BDNF effects also connect it to the neurobiological framework of mood disorders. The Russian clinical studies exploring Selank in anxious depression, mixed anxiety-depressive states, and stress-related mood disturbance reflect a clinical tradition that recognizes this overlap in ways that Western diagnostic categories sometimes obscure.

NAD+ — nicotinamide adenine dinucleotide — is not a peptide but appears in this landscape because of its role in cellular energy metabolism, its relationship to serotonin precursor metabolism, and some preclinical work suggesting it may have direct effects on mood-relevant pathways. NAD+ is required for the enzymatic conversion steps in tryptophan metabolism, and its depletion under chronic stress and inflammatory conditions may contribute to the kynurenine pathway diversion that reduces serotonin availability. There are small clinical studies and case reports suggesting IV NAD+ infusion may produce rapid mood-elevating effects in some patients, potentially through mechanisms overlapping with the fast-acting antidepressant effects of ketamine. This is preliminary; the NAD+ and depression connection is mechanistically interesting but lacks the large controlled trial evidence that would support confident clinical application. NAD+ infusion is available through compounding and IV wellness clinics, and while it carries a reasonable safety profile in most contexts, the antidepressant application is speculative.

PE-22-28, a synthetic peptide studied primarily in animal models, represents a more experimental thread in the mood research landscape. It is designed to block the TREK-1 potassium channel — a channel that has been identified as a potential antidepressant target based on findings that mice lacking TREK-1 are resistant to depressive behavior in standard animal models and show elevated serotonin levels. This is preclinical data; the TREK-1 hypothesis is interesting but far from clinically validated. PE-22-28 represents the frontier research edge of peptide mood applications — worth understanding as a directional indicator of where some research is going, not as something with a developed clinical evidence base.

Cortexin, a polypeptide complex derived from cortical bovine brain tissue, is used clinically in Russia and some Eastern European countries for cognitive and neurological applications including depression. Like Cerebrolysin, it provides a mixture of neurotrophic peptides rather than a single defined compound, and it has been studied in depression with mixed and preliminary results. It is not available through conventional Western pharmaceutical channels and is mentioned here as context for the Russian nootropic and neurological peptide tradition, which has a longer clinical history with these compounds than Western medicine typically acknowledges, even if that history doesn't translate directly into Western evidentiary standards.

Oxytocin's relevance to depression runs through the social engagement pathway. Depression frequently involves social withdrawal — the anhedonic disconnection from relationships that is both a symptom and a perpetuating factor of the depressive state. Oxytocin modulates social threat sensitivity, promotes affiliative behavior, and blunts the fear and rejection responses that can make social engagement feel effortful or threatening during depressive episodes. Some research has explored intranasal oxytocin in the context of social anhedonia and depression, and while the clinical results have been mixed, the mechanistic case for why the social engagement pathway matters in depression is strong. The evidence for social connection as an antidepressant in a broader sense — not intranasal oxytocin specifically, but genuine social engagement — is among the most consistent in the mood literature.

The neuroinflammation intersection is where BPC-157, KPV, and VIP enter the mood picture indirectly. For people whose depressive state has a significant inflammatory driver — elevated hs-CRP, a history consistent with inflammatory illness, gut microbiome dysbiosis — reducing systemic inflammation is hypothetically relevant to mood, even if the mechanism is indirect. BPC-157's gut barrier effects, KPV's NF-kB pathway anti-inflammatory activity, and VIP's broad anti-inflammatory signaling could theoretically reduce the inflammatory cytokine burden that contributes to the kynurenine pathway diversion. This is speculative in the mood application specifically; it is an indirect argument based on mechanism rather than direct clinical evidence in depressed patients.

The conventional pharmacotherapy hierarchy needs to be stated clearly. SSRIs and SNRIs have demonstrated efficacy in large controlled trials for major depressive disorder, and that evidence base — while far from perfect — is substantial. For treatment-resistant depression, ketamine and its enantiomer esketamine (FDA-approved in nasal spray form) represent a genuine advance — fast-acting, with effects in patients who have failed multiple conventional antidepressants. Bupropion acts through different mechanisms and suits different presentations. Lithium, for bipolar spectrum conditions, has decades of evidence and a protective effect on suicidal ideation that few other agents match. Psychotherapy — particularly cognitive-behavioral therapy and behavioral activation — has strong evidence for mild to moderate depression and is effective in combination with pharmacotherapy for severe presentations. These are the primary therapies for a reason, and they should be considered and optimized before anything in the peptide research landscape.

The risk consideration here requires direct language. Depression carries serious morbidity and mortality. Untreated or undertreated depression is associated with functional impairment, relationship deterioration, medical consequences from behavioral changes, and — at the severe end — suicidal ideation and completed suicide. The appeal of researching alternative approaches is understandable, especially for people who have had disappointing experiences with conventional antidepressants or who are skeptical of a medical system that sometimes treats depression with eight-minute appointments and prescription pads. But the danger of following that research interest down a peptide path while delaying or discontinuing specialist evaluation and conventional treatment is real. Chasing adjunctive approaches without adequate primary treatment can allow a serious condition to progress in the background.

The appropriate framing is not either/or. A competent integrative psychiatrist or psychiatric provider will evaluate the full picture — HPA axis function, inflammatory markers, thyroid, sleep architecture, substance use, trauma history, medication trial history — and work with you to understand which conventional approaches you've tried, what worked, what didn't, and what the evidence supports for your specific presentation. Within that context, and with conventional management optimized or clearly understood, the question of whether adjunctive peptide approaches might offer additional support is a legitimate one. The neuroinflammatory patient who has adequate SSRI coverage but persistent inflammatory depressive symptoms might be a different candidate for an anti-inflammatory adjunct than the patient with classical monoamine-deficiency depression and a good SSRI response. These distinctions require clinical evaluation, not protocol matching.

Depression research is moving in directions that vindicate the biological complexity that patients have always lived with — the sense that "low serotonin" was never quite the full story. The peptide research threads that intersect with BDNF, neuroinflammation, the kynurenine pathway, and HPA dysregulation are touching real biology. They are preliminary. They are adjunctive at best. And they matter most when held within a relationship with a mental health specialist who takes the full complexity of your presentation seriously.